Source comparison
CJC-1295 no DAC & Ipamorelin Oral vs Injectable: Delivery Route Comparison
The table below summarizes the core differences between oral and injectable delivery for CJC-1295 no DAC & Ipamorelin—bioavailability, mechanism preservation, dosing precision, and practical outcomes. | Delivery Route | Bioavailability | Mechanism Integrity |
This comparison does not assign a generated winner or score.
- The table below summarizes the core differences between oral and injectable delivery for CJC-1295 no DAC & Ipamorelin—bioavailability, mechanism preservation, dosing precision, and practical outcomes.
- | Delivery Route | Bioavailability | Mechanism Integrity | Dosing Precision | Storage Requirements | Typical Research Outcomes | Bottom Line ||—|—|—|—|—|—|| Injectable (Subcutaneous) | 90–100%. Peptide enters circulation intact without first-pass metabolism | Fully preserved. Peptide reaches pituitary receptors in active form, triggering GH pulse | Exact. Dose administered equals dose absorbed (±5%) | Lyophilised: −20°C; Reconstituted: 2–8°C, use within 28 days | Measurable GH elevation within 30–60 minutes; dose-dependent anabolic signaling; reproducible across trials | Injectable is the only delivery route that delivers CJC-1295 no DAC & Ipamorelin at therapeutic concentration to target receptors. Oral fails the bioavailability test before mechanism matters || Oral (Capsule/Tablet) | <5%. Peptide bonds cleaved by pepsin, trypsin, chymotrypsin; degraded fragments lack receptor affinity | Destroyed. Enzymatic hydrolysis dismantles peptide structure before systemic absorption | Unknown.